Company intelligence / Profile preview

AtG Therapeutics

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

AtG Therapeutics develops small molecule drug candidates and biomarkers to prevent tumor adaptation and resistance in cancer. The company’s approach focuses on novel mechanisms of action targeting vulnerabilities in both treatment-naïve and resistant patients. As a pre-clinical stage company, no clinical results are available yet.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

AtG-153

Preclinical

Partnerships

Spin-off from Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institute of Oncology (ICO), Barcelona, Spain—implying close collaboration with these institutions.

Beyond the preview

Go deeper on AtG Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtG Therapeutics.